Sulfadoxine-Pyrimethamine + Amodiaquine Tablets are a well-established Fixed-Dose Combination (FDC) antimalarial, designed for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum (including chloroquine-resistant strains) and Plasmodium vivax. By integrating three agents with distinct mechanisms of action, the tablets deliver rapid parasite clearance while minimizing the risk of developing drug resistance.
The formulation leverages the synergistic effects of:
Sulfadoxine: A sulfonamide antibiotic that blocks parasite folate synthesis by inhibiting dihydropteroate synthase (DHPS).
Pyrimethamine: A folic acid antagonist that targets dihydrofolate reductase (DHFR), disrupting the final step of folate metabolism.
Amodiaquine: A 4-aminoquinoline that interferes with parasite nucleic acid metabolism, killing the erythrocytic schizont stage directly.
This triple-action strategy ensures broad-spectrum efficacy and accelerates patient recovery, making it a preferred choice for malaria-endemic regions.
Indications
Treatment of acute uncomplicated malaria caused by P. falciparum (including multidrug-resistant strains) and P. vivax.
Prophylaxis (preventive use) in high-risk populations, under medical supervision.
Suitable for adults and children aged 2 years and above.
Key Features
Rapid Parasite Clearance: Dual folate pathway inhibition + nucleic acid disruption targets malaria parasites at multiple stages, ensuring fast resolution of symptoms.
High Resistance Coverage: Effective against strains resistant to single-agent antimalarials (e.g., chloroquine), reducing treatment failure rates.
Convenient Dosing: Single-dose or short 3-day course regimens improve patient compliance, especially for remote communities.
Quality Assured: Manufactured under strict GMP guidelines, compliant with USP/EP/CP pharmacopoeial standards. Complete regulatory documentation (DMF/COS) available for global market registration.
Stable Formulation: Optimized for storage in hot, humid malaria-endemic environments without compromising potency.
Dosage & Administration
For oral use only. Follow medical guidance.
Adults (≥18 years): Single oral dose (standardized by age/weight) or 3-day consecutive course (typical regimen: 1 tablet on Day 1, 1 tablet on Day 2/3, adjusted for severity).
Children (2–17 years): Weight-based dosage adjustment, administered under adult supervision.
Strictly avoid overdose; adhere to local treatment guidelines.
Storage
Store in a cool, dry place (15–25°C), protected from light, moisture, and heat. Keep out of reach of children.
Important Notes
Contraindications: Hypersensitivity to sulfonamides, quinoline derivatives, or any component of the formulation; severe hepatic/renal impairment; pregnant individuals (first trimester); lactating mothers.
Adverse Reactions: May include nausea, vomiting, rash, or headache. Discontinue and seek medical care if severe reactions (e.g., hepatic toxicity, hematological disorders) occur.
Drug Interactions: Avoid co-administration with other sulfonamide-containing medications or antifolates (e.g., trimethoprim).
Special Populations: Geriatric patients, children, and individuals with comorbidities (e.g., anemia, diabetes) require close monitoring during treatment.
This is a prescription medication. Use only under the guidance of a qualified healthcare provider.
